Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Immunology

Pathology

Dermatology

Internal Medicine

Show all topics

DOI

10.1016/s0140-6736(19)30952-3